IHF:NYE-iShares U.S. Healthcare Providers ETF (USD)

ETF | Health |

Last Closing

USD 57.33

Change

-0.20 (-0.35)%

Market Cap

N/A

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-20 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.64 (-0.41%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

-0.50 (-0.68%)

USD 3.02B
FXH First Trust Health Care AlphaD..

-0.94 (-0.83%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.36 (-0.40%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.27 (-1.07%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.13 (-0.34%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.92 (-0.94%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.36 (-1.21%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.44 (-0.68%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.20 (-0.68%)

USD 0.01B

ETFs Containing IHF

LCR Leuthold Core ETF 0.00 % 0.00 %

-0.15 (-0.42%)

USD 0.09B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.18% 43% F 55% F
Dividend Return 0.25% 40% F 4% F
Total Return 9.43% 43% F 47% F
Trailing 12 Months  
Capital Gain 14.84% 10% F 51% F
Dividend Return 0.85% 56% F 10% F
Total Return 15.69% 14% F 44% F
Trailing 5 Years  
Capital Gain 68.22% 90% A- 78% C+
Dividend Return 4.27% 61% D- 12% F
Total Return 72.49% 86% B+ 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 9.25% 90% A- 67% D+
Dividend Return 9.88% 81% B- 62% D
Total Return 0.63% 63% D 14% F
Risk Return Profile  
Volatility (Standard Deviation) 16.94% 57% F 59% D-
Risk Adjusted Return 58.29% 71% C- 76% C+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:

There is nothing we particularly dislike